Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients

Summary

This is a randomized, double-blind, placebo-controlled, adaptive two-stage design, human phase 2 study, with add-on treatment arrangement of fluvoxamine or placebo on top of standard of care (base therapy: the actual proposed therapy of moderate SARS-CoV-2 infected patients according to "Hungarian Coronavirus Handbook", including antiviral and immunmodulant therapy and reconvalescent plasma therapy in serious cases as indicated by the investigator).

Timeline

Start

2020-11-27

Primary completion

2022-03-15

Completion

2022-05-31

Drugs

Indications